• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Intranasal norovirus vaccine capable of reducing infection

An article published in the December 8, 2011 issue of the New England Journal of Medicine describes a proof of principle study in which an intranasal dry powder vaccine significantly reduced Norwalk virus gastroenteritis and infection in study participants innoculated with Norwalk virus. LigoCyte Pharmaceuticals created the vaccine from virus-like particles since norovirus cannot be grown under laboratory conditions.

Researchers from Baylor College of Medicine were part of a consortium that dosed 90 participants with the dry powder vaccine or a placebo inactive vaccine. After three weeks, 84 of the participants were innoculated with the virus. Just over a third of the participants who received the active vaccine developed gastroenteritis compared to slightly more than two thirds of those who received the placebo. Vaccine recipients who became ill experienced less severe symptoms than did the unvaccinated participants who became ill. Although only 37% of the participants vaccinated developed symptoms, 61% became infected compared to approximately 80% who got the placebo.

Mary Estes, Professor of molecular virology and microbiology at Baylor commented, “these studies show for the first time that a non-replicating vaccine given intranasally can induce protection against a gastrointestinal pathogen. We had been told this couldn’t be done.”

LigoCyte CEO Donald Beeman added, “We look forward to continued development of our VLP (virus-like particle)-based norovirus vaccine candidates including additional clinical studies of our bivalent intramuscular vaccine.” The intramuscular vaccine is the company’s lead product, and the intranasal formulation is an alternate candidate.

Read the abstract.
Read a Baylor College of Medicine press release.

Share

published on December 12, 2011

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews